GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets hard-to-treat stomach cancer before surgery
Disease control Recruiting nowThis study tests whether adding a targeted drug (LM-302) to standard immunotherapy and chemotherapy before surgery can improve outcomes for people with a specific type of stomach cancer that has a protein called claudin 18.2. About 88 adults with advanced but removable stomach ca…
Matched conditions: GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for stomach cancer patients with abdominal spread
Disease control Recruiting nowThis study tests a combination of drugs (LM-302, S-1, and intraperitoneal paclitaxel) with or without another drug (cadonilimab) in people with a specific type of advanced stomach cancer (Claudin 18.2-positive) that has spread to the lining of the abdomen. The goal is to see if t…
Matched conditions: GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC